Alpha-Ketoglutarate (AKG): The Krebs Cycle Metabolite Linked to 8 Years of Biological Age Reversal (2026)

Most longevity compounds come from outside your body. They are plant extracts, synthesized molecules, or vitamins your cells cannot manufacture on their own. Alpha-ketoglutarate is different. It is a metabolite (a molecule produced by your own metabolism) that sits at the exact center of the Krebs cycle – the energy-generating process that keeps every cell in your body alive. You are making it right now.

The problem is that you are making far less of it than you used to.

Plasma AKG concentrations decline approximately ten-fold between the ages of 40 and 80 (Harrison & Pierzynowski, Journal of Physiology and Pharmacology, 2008). That is not a modest decline. That is a metabolic cliff. And a growing body of evidence suggests this collapse is not merely a symptom of aging – it may be actively accelerating it. In mice, supplementing calcium alpha-ketoglutarate (CaAKG) extended median lifespan by 12% and reduced frailty by over 40% (Asadi Shahmirzadi et al., Cell Metabolism, 2020). In a small human study, a CaAKG-based formulation appeared to reverse biological age by an average of eight years in just seven months (Demidenko et al., Aging, 2021).

Those numbers demand scrutiny. This article provides it – along with everything else the evidence currently supports about AKG and aging.

TL;DR – Key Takeaways

• AKG is a central Krebs cycle metabolite that your body produces naturally – but plasma levels drop ~10x between ages 40 and 80
• In mice, calcium AKG (CaAKG) extended median lifespan by 12% in females and reduced frailty index by over 40%
• A 2021 human retrospective study (n=42) showed an average 8-year decrease in biological age after 7 months of CaAKG supplementation – but the study design has significant limitations
• AKG acts as a cofactor for TET enzymes (which demethylate DNA) and Jumonji-domain histone demethylases – directly modifying the epigenetic landscape your biological age clocks measure
• The ABLE trial (NCT05706389), a proper double-blind RCT with 120 participants, is underway and will provide much stronger evidence
• Common supplemental dose: 300 mg–1 g/day as calcium alpha-ketoglutarate, taken with food
• GRAS status (Generally Recognized As Safe) – well-tolerated in human studies to date

What Is Alpha-Ketoglutarate?

Alpha-ketoglutarate (also written as α-ketoglutarate or AKG) is a five-carbon organic acid that functions as a key intermediate in the Krebs cycle (also called the TCA cycle or citric acid cycle) – the metabolic pathway inside your mitochondria that generates the electron carriers NADH and FADH2 used to produce ATP, your cells' primary energy currency.

To understand AKG's position, picture the Krebs cycle as a circular assembly line with eight stations. AKG sits at station five. It is produced when isocitrate (the molecule at station four) is oxidized by the enzyme isocitrate dehydrogenase. AKG is then converted to succinyl-CoA by the alpha-ketoglutarate dehydrogenase complex – a reaction that generates one molecule of NADH and one molecule of CO2. Every turn of the cycle passes through AKG.

But AKG is not just a Krebs cycle waypoint. It is a metabolic nexus with at least four distinct roles:

1. Energy metabolism. As described, AKG is required for each complete turn of the Krebs cycle. Less AKG means less efficient mitochondrial energy production. For more on why mitochondrial function is central to aging, see The Mitochondrial Theory of Aging.

2. Nitrogen metabolism. AKG is the primary acceptor of amino groups in transamination reactions (reactions that transfer nitrogen-containing groups between molecules). This makes it essential for amino acid synthesis and for disposing of excess nitrogen as urea. When AKG levels fall, protein synthesis and nitrogen detoxification both become less efficient.

3. Epigenetic regulation. This is where AKG becomes directly relevant to aging. AKG is a required cofactor (a molecule that an enzyme needs to function) for a family of enzymes called 2-oxoglutarate-dependent dioxygenases. This family includes TET enzymes (ten-eleven translocation enzymes, which remove methyl groups from DNA) and Jumonji-domain histone demethylases (which remove methyl groups from histone proteins that DNA wraps around). Both enzyme classes directly reshape the epigenetic landscape – the layer of chemical modifications that controls which genes are active without changing the DNA sequence itself.

4. Signaling. AKG activates AMPK (AMP-activated protein kinase, the cell's energy-sensing switch that promotes repair and maintenance), inhibits mTOR (mechanistic target of rapamycin, the growth-promoting pathway whose suppression extends lifespan across species), and stabilizes HIF-1α (hypoxia-inducible factor 1-alpha, a transcription factor involved in oxygen-sensing and metabolic adaptation). For a deeper dive into the AMPK/mTOR axis, see mTOR and AMPK: The Aging Switches Inside Every Cell.

No other single metabolite simultaneously feeds the Krebs cycle, regulates nitrogen disposal, modifies the epigenome, and modulates the two most-studied longevity signaling pathways. AKG is not a niche compound. It is infrastructure.

Key Takeaway: AKG is not just another supplement ingredient – it is a central metabolic node that simultaneously powers the Krebs cycle, regulates nitrogen disposal, modifies the epigenome via TET enzymes, and modulates both AMPK and mTOR longevity pathways. No other single metabolite touches this many aging-relevant systems at once.

Why AKG Declines With Age

The decline is dramatic and well-documented. Harrison and Pierzynowski measured circulating AKG levels across the human lifespan and found that plasma concentrations at age 80 are approximately one-tenth of levels at age 40 (Journal of Physiology and Pharmacology, 2008). The decline is not linear – it accelerates in midlife, with particularly steep drops between ages 40 and 60.

Several mechanisms contribute to this collapse:

Mitochondrial dysfunction. As mitochondria accumulate damage with age – from reactive oxygen species (ROS, chemically reactive molecules containing oxygen that damage cellular components), mtDNA mutations (mutations in mitochondrial DNA), and declining membrane potential – the efficiency of the Krebs cycle decreases. Each enzyme in the cycle runs slower. Flux through the entire pathway drops, and intermediate metabolites including AKG are produced at lower rates.

Reduced NAD+ availability. The Krebs cycle depends on NAD+ (nicotinamide adenine dinucleotide, an essential coenzyme) as an electron acceptor. NAD+ levels decline substantially with age – roughly 50% between ages 40 and 60 in some tissues. When NAD+ is limiting, the cycle slows, and AKG production falls. For more on this related decline, see What Is NMN? The NAD+ Precursor Explained.

Decreased physical activity. Exercise is one of the most potent stimulators of Krebs cycle flux. Sedentary behavior, which increases with age, means fewer complete turns of the cycle per unit of time and lower steady-state AKG concentrations.

Increased consumption. Aging is characterized by heightened oxidative stress (an imbalance between reactive oxygen species and your body's ability to neutralize them) and chronic inflammation. Both increase the demand for AKG as a cofactor in antioxidant and repair reactions, pulling it away from its other roles.

The consequence is a metabolic squeeze: the body produces less AKG while simultaneously demanding more of it. The result is a progressive deficit that impairs energy production, epigenetic maintenance, and cellular signaling all at once.

This is not a fringe observation. The age-related decline of AKG parallels and may partly explain the functional decline of the mitochondria, the epigenome, and the nutrient-sensing pathways that define the hallmarks of aging.

Key Takeaway: AKG levels drop approximately 10-fold between ages 40 and 80 – a metabolic cliff driven by mitochondrial dysfunction, declining NAD+, reduced physical activity, and increased oxidative demand. This decline impairs energy production, epigenetic maintenance, and longevity signaling all at once. Supplementation provides AKG directly rather than relying on impaired endogenous production.

The Mouse Data: Lifespan Extension and Frailty Reduction

The landmark preclinical study was published in September 2020 by Asadi Shahmirzadi and colleagues in Cell Metabolism – one of the top-tier journals in metabolic research. The study is rigorous, well-powered, and has been widely cited. Here is what they found.

Study Design

The researchers administered calcium alpha-ketoglutarate (CaAKG) to C57BL/6 mice (a standard laboratory mouse strain) beginning at 18 months of age – roughly equivalent to late middle age in humans (approximately age 55–60). CaAKG was mixed into the chow (food) at a concentration of 2% by weight. A control group received identical chow without CaAKG. The study tracked survival, frailty, and multiple healthspan biomarkers until natural death.

Lifespan Results

Female mice fed CaAKG showed a statistically significant 12% extension of median lifespan compared to controls. This is a substantial effect – comparable to some caloric restriction protocols and better than many pharmacological interventions tested in mice.

Male mice did not show a statistically significant extension of median lifespan, though there was a trend toward increased survival. The sex difference is not fully explained but is not unusual in mouse longevity studies – interventions that target metabolic and hormonal pathways frequently show different effect sizes in males and females.

Frailty Results

This is where the data becomes particularly compelling. The researchers assessed frailty using a validated 31-parameter index that measures coat condition, gait, hearing, grip strength, body weight, and many other age-associated markers. CaAKG-treated female mice showed a 46% reduction in frailty index compared to age-matched controls. Males showed a smaller but still meaningful reduction.

To be concrete: a frailty index reduction of this magnitude means the treated mice looked and functioned as if they were substantially younger than their untreated counterparts. They had better coats, stronger grips, better hearing, and more normal body composition. This is not just longer life – it is longer functional life.

Mechanistic Findings

The study also demonstrated that CaAKG treatment:

• Reduced chronic inflammation. Levels of IL-6 (interleukin-6, a pro-inflammatory cytokine) were significantly lower in treated mice. Chronic, low-grade inflammation – sometimes called "inflammaging" – is a key driver of age-related disease.
• Suppressed age-related gene expression changes. RNA sequencing of tissues from treated mice showed expression patterns closer to younger mice than to untreated aged controls.
• Did not simply act through caloric restriction. Food intake and body weight were similar between treated and control groups, ruling out a simple reduction in calorie consumption as the mechanism.

Caveats

Mouse lifespan studies always carry the caveat that mice are not humans. The 12% median lifespan extension in females is promising, but the lack of significance in males tempers enthusiasm. The study used a single mouse strain (C57BL/6), and genetic background can substantially influence responses to longevity interventions. The dose (2% of chow by weight) is high relative to typical human supplementation, though CaAKG has good oral bioavailability and GRAS status in humans at relevant doses.

Still, this is among the stronger mouse longevity datasets for a naturally occurring, well-tolerated metabolite.

Key Takeaway: CaAKG extended median lifespan by 12% in female mice and reduced frailty by 46% – meaning treated mice looked and functioned as substantially younger than their actual age. The effect was achieved without caloric restriction. While mouse data does not directly translate to humans, this is one of the stronger preclinical longevity datasets for a naturally occurring metabolite.

The Human Evidence: Biological Age Reversal

In 2021, Demidenko and colleagues published a retrospective study in the journal Aging that produced a headline-grabbing result: an average eight-year decrease in biological age after seven months of CaAKG supplementation (Demidenko et al., Aging, 2021; PMID 33819162).

Study Design

This was a retrospective analysis of 42 individuals (14 female, 28 male, average age approximately 62 years) who had been taking a commercially available CaAKG-based formulation containing additional vitamins (A and D). All subjects had their biological age measured using the TruAge test – a DNA methylation-based epigenetic clock (a method that estimates biological age by measuring chemical modifications to DNA at specific sites across the genome) – both before starting supplementation and again after an average of seven months.

Results

The average decrease in biological age was approximately 8 years. Some individuals showed even larger reversals. The effect was observed in both men and women, though the sample sizes were too small to reliably detect sex-specific differences.

To put this in context: an 8-year reduction in biological age would be among the largest effects documented for any single intervention. Caloric restriction, exercise, and pharmaceutical interventions like rapamycin analogs typically show biological age reductions of 1–3 years in human studies.

Why You Should Be Cautious

This study has real methodological limitations that must be acknowledged honestly:

No placebo control. Without a control group taking an identical-looking placebo, you cannot distinguish the AKG effect from regression to the mean (the statistical tendency for extreme measurements to move closer to average on retesting), the placebo effect, seasonal variation in epigenetic markers, or any other confounding variable.

Retrospective design. The researchers did not assign participants to treatment. They analyzed people who had already chosen to take CaAKG and had biological age data. This introduces self-selection bias – people who seek out CaAKG supplementation may also engage in other health-promoting behaviors (exercise, sleep optimization, dietary changes) during the study period.

Small sample size. With only 42 participants and no control arm, the confidence intervals around the 8-year estimate are wide. The true population effect could be meaningfully larger or smaller.

The formulation contained vitamins A and D. These are not inert additions. Vitamin D status, in particular, has been associated with DNA methylation patterns. Some portion of the observed effect could be attributable to these co-supplements rather than CaAKG alone.

Single epigenetic clock. Biological age was measured using one specific DNA methylation test. Different epigenetic clocks can give different results for the same individual. Reproducibility across multiple clock systems would strengthen the finding.

No long-term follow-up. We do not know whether the biological age reduction persisted, reversed, or continued to improve after seven months.

The 8-year number is intriguing enough to demand a proper randomized controlled trial. It is not, by itself, sufficient to claim that CaAKG reverses aging. The authors themselves acknowledged these limitations and called for prospective, controlled studies.

Key Takeaway: The 8-year biological age reversal signal is intriguing but comes from a small, uncontrolled retrospective study with significant methodological limitations. Treat it as a preliminary signal that justifies further research – not as confirmed evidence. The ABLE trial (NCT05706389) will provide much stronger data.

The ABLE Trial: What We Are Waiting For

The study that will provide much stronger evidence is the ABLE trial (Aging Biomarker Levels after Enrichment), registered as NCT05706389 on ClinicalTrials.gov.

Study Design

• Type: Double-blind, randomized, placebo-controlled trial – the gold standard for clinical evidence
• Participants: 120 adults aged 40–60
• Intervention: 1 g per day of sustained-release calcium alpha-ketoglutarate vs. matched placebo
• Duration: 6 months of treatment plus 3 months of follow-up
• Primary endpoints: Changes in biological age as measured by DNA methylation clocks (multiple clocks, addressing a weakness of the Demidenko study), along with standard aging biomarkers
• Secondary endpoints: Frailty measures, inflammatory markers, metabolic parameters, safety data

Why This Trial Matters

The ABLE trial corrects for every major weakness of the Demidenko retrospective:

• It has a placebo control, eliminating regression-to-the-mean artifacts
• It is prospective and randomized, removing self-selection bias
• It is adequately powered (120 participants is sufficient to detect a clinically meaningful biological age change)
• It uses multiple epigenetic clocks, providing cross-validation
• It includes a 3-month washout period, allowing assessment of effect persistence
• CaAKG is the sole active ingredient, isolating its effect from confounders

As of March 2026, results have not yet been published. When they are, they will either validate the provocative signal from the Demidenko study or reveal it to have been an artifact. Either outcome will substantially advance our understanding of AKG and human aging.

How AKG May Slow Aging: Mechanisms of Action

David Sinclair on why metabolites like AKG matter for aging:

The biological plausibility for AKG as a longevity compound is unusually strong. It intersects multiple established aging mechanisms simultaneously. Here is the mechanistic case, pathway by pathway.

AMPK Activation

AMPK (AMP-activated protein kinase) is the master energy sensor of the cell. When cellular energy status drops – when the AMP-to-ATP ratio rises – AMPK activates and triggers a cascade of maintenance and repair programs: autophagy (the cell's internal recycling process), mitochondrial biogenesis (the creation of new mitochondria), enhanced fatty acid oxidation, and suppression of energy-consuming biosynthetic pathways.

AKG activates AMPK, likely through indirect mechanisms including modulation of cellular energy status via its role in the Krebs cycle and downstream metabolic signaling. AMPK activation is one of the most consistently identified mechanisms across longevity interventions – it is shared by caloric restriction, exercise, metformin, and resveratrol.

For a comprehensive treatment of why AMPK activation matters for aging, see mTOR and AMPK: The Aging Switches Inside Every Cell.

mTOR Inhibition

mTOR (mechanistic target of rapamycin) is the growth-promoting counterpart to AMPK. When nutrients are abundant, mTOR drives cell growth, proliferation, and protein synthesis. This is beneficial during development and wound healing, but chronic mTOR activation in aging accelerates cellular senescence (the permanent growth arrest of damaged cells), suppresses autophagy, and promotes the accumulation of damaged proteins and organelles.

AKG inhibits mTOR signaling. The downstream effects include enhanced autophagy, reduced cellular senescence, and improved proteostasis (the maintenance of properly folded, functional proteins). Rapamycin, the most well-validated pharmacological longevity compound in animal models, works through the same target – see Rapamycin: The Drug That Extended Lifespan in Every Species Tested.

The simultaneous activation of AMPK and inhibition of mTOR positions AKG as a potential caloric restriction mimetic – a compound that recapitulates the longevity benefits of eating less without actually reducing food intake. The Asadi Shahmirzadi mouse study supports this interpretation: CaAKG-treated mice showed longevity benefits without changes in food consumption or body weight.

HIF-1α Stabilization

HIF-1α (hypoxia-inducible factor 1-alpha) is a transcription factor (a protein that controls gene expression) that normally activates under low-oxygen conditions. It upregulates genes involved in metabolic adaptation, angiogenesis (new blood vessel formation), and stress resistance. Under normal oxygen levels, HIF-1α is rapidly degraded by prolyl hydroxylases – enzymes that use AKG as a cofactor.

The relationship between AKG and HIF-1α is nuanced. AKG is required for the prolyl hydroxylases that degrade HIF-1α, but the overall effect of AKG supplementation on HIF-1α stabilization depends on the cellular context – the ratio of AKG to its competitor succinate, oxygen levels, and the activity of other cofactors. In aging tissues, where mitochondrial dysfunction often creates a pseudo-hypoxic state (cells behaving as if oxygen is low when it is not), AKG supplementation may help normalize the HIF-1α response rather than simply pushing it in one direction.

Anti-Inflammatory Effects

The Asadi Shahmirzadi mouse study demonstrated that CaAKG-treated mice had significantly lower levels of IL-6, a key pro-inflammatory cytokine. Chronic low-grade inflammation – "inflammaging" – is now recognized as both a hallmark and a driver of biological aging. It promotes tissue damage, impairs regeneration, accelerates telomere shortening, and drives cellular senescence.

AKG's anti-inflammatory effect appears to operate through multiple mechanisms: NF-κB suppression (NF-κB is the master inflammatory transcription factor), reduced production of pro-inflammatory prostaglandins, and indirect effects via improved mitochondrial function (damaged mitochondria release DAMPs – damage-associated molecular patterns – that trigger inflammatory responses).

AKG and Epigenetic Clocks: The DNA Demethylation Connection

This section is critical for understanding why the biological age reversal signal in the Demidenko study is mechanistically plausible – not just a random finding.

What Epigenetic Clocks Measure

Epigenetic clocks – Horvath's clock, GrimAge, PhenoAge, DunedinPACE, and others – estimate biological age by measuring DNA methylation (the addition of methyl groups to cytosine bases in DNA) at specific genomic locations called CpG sites (regions where a cytosine is followed by a guanine in the DNA sequence). As you age, methylation patterns drift in predictable ways: some sites gain methyl groups, others lose them. The pattern of drift correlates powerfully with chronological age, disease risk, and mortality.

For a full explanation of how these clocks work and what they measure, see Biological Age Testing: The Complete Guide.

AKG Directly Modifies What Clocks Read

Here is the mechanistic link that makes AKG uniquely relevant to epigenetic aging:

TET enzymes (TET1, TET2, TET3) are the primary enzymes responsible for active DNA demethylation – the removal of methyl groups from DNA. They convert 5-methylcytosine (5mC, the standard methylation mark) to 5-hydroxymethylcytosine (5hmC), which is then further processed and ultimately replaced by unmethylated cytosine. This process is how cells actively maintain and adjust their epigenetic programming.

TET enzymes absolutely require AKG as a cofactor. Without AKG, TET enzymes cannot function. As AKG levels decline with age, TET enzyme activity declines proportionally, and the cell's ability to actively demethylate DNA erodes. This contributes to the progressive drift in DNA methylation patterns that epigenetic clocks detect as aging.

Jumonji-domain histone demethylases are another family of 2-oxoglutarate-dependent dioxygenases that require AKG. These enzymes remove methyl groups from histone proteins (the protein spools around which DNA is wound). Histone methylation patterns control gene accessibility – which genes can be read and which are silenced. Age-related drift in histone methylation contributes to the progressive dysregulation of gene expression seen in aged tissues.

The Mechanistic Prediction

If AKG supplementation restores sufficient cofactor availability to re-activate TET enzymes and Jumonji-domain demethylases, you would predict exactly what the Demidenko study appeared to show: a reversal in the methylation patterns that epigenetic clocks measure as biological age.

This is not a post-hoc rationalization. The enzymatic relationship between AKG and TET enzymes was established in the biochemistry literature (Tahiliani et al., Science, 2009; Ito et al., Nature, 2010) well before anyone measured biological age in response to AKG supplementation. The prediction flows naturally from known biochemistry.

It is also worth noting what this mechanism implies about specificity. AKG does not randomly alter DNA methylation – it restores the activity of the enzymatic machinery that maintains proper methylation patterns. This is epigenetic correction, not epigenetic noise. In theory, restoring TET function should push methylation patterns back toward their youthful configuration, not toward some arbitrary state.

The Succinate Competition

One additional detail matters for understanding AKG's epigenetic effects. Succinate (the metabolite one step downstream from AKG in the Krebs cycle) is a competitive inhibitor of TET enzymes and other 2-oxoglutarate-dependent dioxygenases. It binds to the same active site as AKG but does not support catalysis – it blocks the enzyme.

In aging and in many disease states, the succinate-to-AKG ratio shifts in favor of succinate. This means TET enzymes are being simultaneously starved of their required cofactor (less AKG) and actively blocked by a competitor (more succinate). Supplementing AKG shifts this ratio back, providing a double benefit: more substrate and relatively less inhibitor.

This succinate/AKG ratio is now recognized as a key regulator of the cellular epigenetic state and has been directly implicated in cancer biology (where aberrant DNA methylation drives tumor progression) and immune cell function (where macrophage polarization between pro-inflammatory and anti-inflammatory states depends in part on this metabolic ratio).

Key Takeaway: AKG is the required cofactor for TET enzymes – the machinery that actively demethylates DNA. As AKG declines with age, TET activity drops, and DNA methylation patterns drift in exactly the ways epigenetic clocks measure as aging. Supplementing AKG may restore TET function and push methylation patterns back toward youthful configurations. This is not post-hoc rationalization – the biochemistry was established before the biological age studies.

Peter Attia and Andrew Huberman discuss longevity supplements including metabolic compounds like AKG:

Practical Guide: Dosing, Timing, and Forms

Forms of AKG

Calcium alpha-ketoglutarate (CaAKG) is the most studied form for longevity applications. It is a calcium salt of AKG that provides both the AKG molecule and supplemental calcium. The Asadi Shahmirzadi mouse study, the Demidenko human study, and the ABLE trial all use CaAKG. The calcium salt is more stable than free AKG, has good oral bioavailability, and has GRAS (Generally Recognized As Safe) status from the FDA.

Free AKG (alpha-ketoglutaric acid) is the unsalted acid form. It is less commonly used in longevity research and can be harsh on the stomach due to its acidity. There is no compelling reason to choose free AKG over CaAKG for longevity purposes.

Arginine alpha-ketoglutarate (AAKG) is widely available in sports nutrition products. It combines AKG with the amino acid arginine and is marketed primarily for nitric oxide support and exercise performance. While AAKG provides AKG, it has not been studied in longevity contexts, and the arginine component adds a variable that complicates comparison to CaAKG research.

Ornithine alpha-ketoglutarate (OKG) is used in clinical settings for muscle wasting and wound healing, particularly in burn patients. Like AAKG, it provides AKG but adds a distinct amino acid (ornithine) with its own biological effects.

Recommendation: For longevity-oriented supplementation, CaAKG is the evidence-based choice.

Dosing

The human studies and trials use doses in the range of 300 mg to 1 g per day of CaAKG. Specifically:

• The Demidenko biological age study used a formulation providing approximately 1 g/day of CaAKG
• The ABLE trial uses 1 g/day of sustained-release CaAKG
• Lower doses (300–600 mg/day) are used in some supplement formulations, though there is less direct evidence supporting these specific doses for longevity outcomes

The Asadi Shahmirzadi mouse study used 2% CaAKG in chow, which translates to a high relative dose. Allometric scaling (adjusting doses between species based on body surface area rather than weight) suggests 1 g/day in humans is a reasonable translational dose, though such scaling is always approximate.

Practical recommendation: 1 g/day of CaAKG is the dose with the most human research support. If cost or tolerance is a concern, 500 mg/day is a reasonable starting point, though the evidence at this specific dose is thinner.

Timing

AKG is an intermediate in energy metabolism, and its absorption is influenced by food intake:

• Take with food. CaAKG is better tolerated with a meal, and co-ingestion with food does not appear to significantly reduce absorption.
• Morning or midday. Given AKG's role in energy metabolism and AMPK activation, morning dosing aligns with circadian metabolic peaks. There is no hard evidence against evening dosing, but there is a theoretical rationale for morning use.
• Consistent daily dosing. Unlike pulse-dosed senolytics, AKG supplementation appears to work through sustained metabolic and epigenetic effects that require continuous availability.

Safety

Safety Note: CaAKG provides supplemental calcium (~200 mg per gram). If you are taking calcium supplements or medications affecting calcium metabolism, account for this additional intake. Individuals with kidney disease or hypercalcemia should consult their physician before use.

AKG has a strong safety profile:

• GRAS status from the FDA, meaning it is considered safe for use in food products
• No serious adverse events reported in published human studies at doses up to 1 g/day
• Most common side effects are mild gastrointestinal symptoms (nausea, stomach discomfort), typically at higher doses or when taken on an empty stomach
• Calcium content: CaAKG provides supplemental calcium. If you are already taking significant calcium supplementation, account for this additional intake. One gram of CaAKG provides approximately 200 mg of elemental calcium.
• Drug interactions: No clinically significant interactions have been identified in published literature, but as with any supplement, inform your physician if you are taking medications – particularly those affecting calcium metabolism or mitochondrial function.

Who Should Be Most Interested

Based on the current evidence, AKG supplementation has the strongest rationale for:

• Adults over 40, when AKG decline accelerates
• Individuals interested in epigenetic age modification
• Those seeking metabolic support for mitochondrial function
• People already tracking biological age who want an intervention with a plausible mechanism of action

Limitations and Open Questions

Intellectual honesty requires acknowledging what we do not know. Here is a candid assessment of the gaps in the AKG longevity evidence.

The human evidence is weak. One retrospective study with 42 participants, no placebo control, and a multi-ingredient formulation is not sufficient to confirm that AKG reverses biological aging in humans. The ABLE trial will help, but as of March 2026, we are still waiting for results from a properly controlled human study.

The mouse lifespan effect was sex-specific. The 12% median lifespan extension was statistically significant only in female mice. The lack of a clear effect in males raises questions about generalizability and mechanism. Is the benefit estrogen-dependent? Does it require a specific hormonal milieu? We do not know.

Optimal dose in humans is not established. The 1 g/day dose used in trials is an educated guess based on the mouse data and pharmacokinetic reasoning. The true dose-response curve in humans for longevity-relevant endpoints has not been characterized.

Duration of effect is unknown. The Demidenko study measured biological age at baseline and after 7 months. We do not know whether the effect plateaus, continues to improve, or reverses upon cessation. The ABLE trial's 3-month follow-up will provide initial data on persistence.

Mechanism confirmation in humans is lacking. The TET enzyme cofactor mechanism is established in biochemistry, but no human study has directly demonstrated that oral CaAKG supplementation increases TET enzyme activity in human tissues or that this mediates the observed biological age changes.

Long-term safety data is limited. While AKG has GRAS status and short-term safety data is reassuring, multi-year safety data for longevity-oriented supplementation does not exist.

The epigenetic clock interpretation is debated. There is an ongoing scientific discussion about whether epigenetic clock "age reversal" represents genuine biological rejuvenation or merely a change in a biomarker that correlates with but does not causally drive aging. Changing the clock reading is not the same as changing the underlying biology – although in AKG's case, the mechanism (TET enzyme restoration) provides a plausible causal path.

Interaction effects are unstudied. Many people interested in AKG are also taking other longevity compounds – NMN, resveratrol, rapamycin, metformin, fisetin, and others. How AKG interacts with these compounds in combination is essentially unknown. The NAD+/AKG intersection is particularly interesting: both decline with age, both support Krebs cycle function, and NMN supplementation could theoretically enhance AKG production by restoring NAD+ levels. But this remains speculative.

Publication bias. Positive results are more likely to be published than null results. We may be seeing a biased sample of the evidence – studies that found AKG effects may be overrepresented while null results sit in file drawers.

These are real limitations. They do not invalidate the AKG hypothesis – the mechanistic case is strong, the mouse data is compelling, and the preliminary human signal is provocative. But they mean the evidence is currently at the "promising but unconfirmed" stage, not the "established and validated" stage.

Frequently Asked Questions

Q: Is AKG the same as alpha-ketoglutaric acid?

Yes, but in practice the term "AKG" in longevity contexts almost always refers to calcium alpha-ketoglutarate (CaAKG), which is the calcium salt form used in research. Free alpha-ketoglutaric acid is more acidic and less commonly used as a supplement. When purchasing, look for CaAKG specifically.

Q: Can my body just make more AKG if I eat well and exercise?

Exercise does increase Krebs cycle flux and can transiently raise AKG levels. A nutrient-rich diet supports the metabolic machinery that produces AKG. However, the age-related decline in AKG appears to be driven substantially by mitochondrial dysfunction and NAD+ depletion – factors that diet and exercise alone may not fully overcome in older adults. Supplementation provides AKG directly rather than relying on impaired endogenous production.

Q: How does AKG compare to NMN or resveratrol for longevity?

These compounds target related but distinct mechanisms. NMN restores NAD+ levels, supporting sirtuins and Krebs cycle function. Resveratrol activates SIRT1 and provides polyphenol-based antioxidant effects. AKG directly feeds the Krebs cycle and uniquely acts as a cofactor for epigenetic-modifying enzymes (TET, Jumonji demethylases). They are complementary rather than competitive – each addresses a different bottleneck in the aging process. No head-to-head human trial has compared their longevity effects.

Q: Is the 8-year biological age reversal real?

The measurement was real – the 42 participants did show an average 8-year decrease on the TruAge epigenetic clock after 7 months of supplementation. Whether this represents genuine biological rejuvenation or is partly an artifact of the study design (no control group, multi-ingredient formulation, small sample size) cannot be determined from this study alone. The ABLE trial will provide much stronger evidence. The mechanistic case is plausible, but the number should be treated as preliminary, not confirmed.

Q: Should I take AKG if I'm under 40?

The rationale is weaker for younger adults. AKG levels are still relatively high before age 40, and the age-related decline has not yet reached its steepest phase. Younger adults are unlikely to have the same cofactor deficit driving TET enzyme dysfunction. If you are under 40 and otherwise healthy, the evidence does not strongly support AKG supplementation for longevity. Standard healthspan practices – exercise, sleep, nutrition, stress management – offer far more validated benefits at this age.

Q: Can I take AKG with other supplements?

No clinically significant interactions have been identified. AKG is an endogenous metabolite, and supplementing it at the doses used in research (300 mg–1 g/day) is unlikely to cause pharmacological interactions. However, the combination effects with other longevity compounds (NMN, rapamycin, metformin, etc.) have not been studied. There is a theoretical rationale for combining AKG with NMN (restoring NAD+ may enhance Krebs cycle function that AKG supports), but this remains unvalidated. As with any supplement regimen, consult your physician.

Q: Is AKG approved for anti-aging use?

No. AKG is not approved by any regulatory agency as a treatment for aging. It has GRAS status as a food ingredient and is legally sold as a dietary supplement. The distinction matters: GRAS status means safety has been established for general consumption, not that efficacy for any specific health claim has been validated by regulators.

Related Reading

• Biological Age Testing: The Complete Guide to Measuring How Fast You're Aging
• The 12 Hallmarks of Aging: Why You Age and What Targets Each One
• The Mitochondrial Theory of Aging: Why Your Cellular Power Plants Matter
• Epigenetic Reprogramming: Can We Actually Reverse Aging at the Cellular Level?
• How to Actually Lower Your Biological Age: A Practical Protocol
• NAD+ Decline by Age: The Complete Decade-by-Decade Timeline

Daily Compounds – your habits are dialed. Your cells aren’t. Learn more →